AG
MYGN icon

Advisor Group’s Myriad Genetics MYGN Stock Holding History

Advisor Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$108K Buy
3,929
+542
+16% +$14.9K ﹤0.01% 2884
2019
Q3 		$97K Buy
3,387
+2,334
+222% +$68K ﹤0.01% 2901
2019
Q2 		$30K Buy
1,053
+16
+2% +$452 ﹤0.01% 3700
2019
Q1 		$34K Buy
1,037
+85
+9% +$2.59K ﹤0.01% 3648
2018
Q4 		$27K Buy
952
+189
+25% +$6.8K ﹤0.01% 3612
2018
Q3 		$36K Buy
763
+53
+7% +$2.36K ﹤0.01% 3518
2018
Q2 		$26K Sell
710
-200
-22% -$6.75K ﹤0.01% 3548
2018
Q1 		$27K Buy
910
+100
+12% +$3.38K ﹤0.01% 3505
2017
Q4 		$28K Buy
810
+350
+76% +$11.8K ﹤0.01% 3486
2017
Q3 		$17K Sell
460
-607
-57% -$17.3K ﹤0.01% 3653
2017
Q2 		$28K Buy
1,067
+335
+46% +$7.11K ﹤0.01% 3263
2017
Q1 		$14K Sell
732
-71
-9% -$1.26K ﹤0.01% 3590
2016
Q4 		$14K Buy
803
+37
+5% +$669 ﹤0.01% 3452
2016
Q3 		$15K Buy
766
+310
+68% +$7.86K ﹤0.01% 3333
2016
Q2 		$13K Buy
+456
New +$15.8K ﹤0.01% 3334

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Advisor Group's MYGN Position: Q4 2019 in Review

Advisor Group increased its Myriad Genetics (MYGN) stake by 16% in Q4 2019, buying an estimated $14.9K and bringing the position to 3,929 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #2884.

Advisor Group first reported a position in MYGN in Q2 2016 and has held it in 15 quarters since. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

  • Advisor Group held 3,929 shares of Myriad Genetics worth $108K as of Q4 2019.
  • Advisor Group bought 542 Myriad Genetics shares in Q4 2019, an estimated $14.9K.
  • Myriad Genetics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2884 holding.
  • Advisor Group first reported a position in Myriad Genetics in Q2 2016 and has held it in 15 quarters since.
  • 227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.